XTX Topco Ltd Acquires 23,015 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Key Points

• XTX Topco Ltd increased its stake in Omnicell, Inc. by 316.1%, acquiring a total of 30,295 shares worth approximately $1,059,000 by the end of the first quarter.
• Analysts have varying ratings on Omnicell, with Wells Fargo increasing its price target from $37.00 to $40.00 and a consensus price target of $45.33 classified as a "Moderate Buy."
• Omnicell's recent quarterly revenue was reported at $290.56 million, exceeding estimates and marking a 5% increase from the previous year.

XTX Topco Ltd raised its stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 316.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 30,295 shares of the company's stock after buying an additional 23,015 shares during the quarter. XTX Topco Ltd owned about 0.06% of Omnicell worth $1,059,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Johnson Financial Group Inc. bought a new stake in Omnicell in the 4th quarter valued at $37,000. Headlands Technologies LLC bought a new stake in Omnicell in the 4th quarter valued at $53,000. Huntington National Bank lifted its position in Omnicell by 236.4% in the 4th quarter. Huntington National Bank now owns 1,359 shares of the company's stock valued at $61,000 after acquiring an additional 955 shares in the last quarter. Point72 Hong Kong Ltd bought a new stake in Omnicell in the 4th quarter valued at $101,000. Finally, Corton Capital Inc. bought a new stake in Omnicell in the 4th quarter valued at $208,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Stock Performance

OMCL traded up $0.36 on Wednesday, reaching $30.86. The company had a trading volume of 201,402 shares, compared to its average volume of 565,983. Omnicell, Inc. has a fifty-two week low of $22.66 and a fifty-two week high of $55.74. The stock has a market cap of $1.45 billion, a P/E ratio of 61.65, a P/E/G ratio of 8.88 and a beta of 0.78. The company's fifty day moving average is $29.33 and its 200 day moving average is $32.94. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.24 and a current ratio of 1.42.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.45 EPS for the quarter, beating analysts' consensus estimates of $0.30 by $0.15. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The business had revenue of $290.56 million for the quarter, compared to analyst estimates of $275.57 million. During the same quarter in the prior year, the business earned $0.51 EPS. Omnicell's quarterly revenue was up 5.0% on a year-over-year basis. As a group, analysts predict that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Analyst Ratings Changes

OMCL has been the topic of several recent research reports. Bank of America lifted their price target on shares of Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research note on Friday, May 23rd. Piper Sandler reiterated an "overweight" rating on shares of Omnicell in a research note on Friday, May 23rd. Benchmark lowered their price target on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Wall Street Zen upgraded shares of Omnicell from a "buy" rating to a "strong-buy" rating in a research note on Saturday, July 12th. Finally, Wells Fargo & Company boosted their price objective on shares of Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a research note on Monday, July 21st. Three equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $45.33.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.